Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Breast (Edinburgh, Scotland)|June 5, 2007
Prescribing extended adjuvant letrozoleK Gelmon
Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology|July 1, 1983
Mechanisms of histamine-induced contraction of canine airway smooth muscleS Shore, C G Irvin, T Shenkier, et al.
Seminars in Radiation Oncology|April 21, 1999
Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experienceP Kirkbride, K Gelmon, E Eisenhauer
British Journal of Haematology|March 1, 1995
Frequent association of t(3;14) or variant with other lymphoma-specific translocationsD E Horsman, B K McNeil, M Anderson, et al.
International Journal of Radiation Oncology, Biology, Physics|December 10, 1997
A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancerP Kirkbride, K Gelmon, E Eisenhauer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer AgencyK M Ramadan, T Shenkier, L H Sehn, et al.
Anticancer Research|May 1, 1995
Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivativeG De Jong, K Gelmon, M Bally, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 1998
Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapseP J Hoskins, N Le, R D Gascoyne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2012
Targeting triple-negative breast cancer: optimising therapeutic outcomesK Gelmon, R Dent, J R Mackey, et al.
Anti-Cancer Drug Design|July 20, 2000
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell linesS A Johnstone, K Gelmon, L D Mayer, et al.
Pageof 5